Refine by
Biomarker Testing Articles & Analysis
33 news found
The use of mouse models enables the study of diabetes in a way that closely mirrors the disease in humans, helping to explore disease mechanisms, find biomarkers, and evaluate potential treatments. Ace Therapeutics provides diverse diabetic mouse models targeting type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), and gestational diabetes mellitus (GDM). The T1DM ...
Tempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm physicians with technology that supports the delivery of guideline-directed biomarker testing for patients with non-small cell lung cancer (NSCLC). ...
ByTempus
BIOMARK RECEIVES FUNDING SUPPORTING RESEARCH AND DEVELOPMENT PROJECT FOR CANCER TREATMENT MONITORING Vancouver, British Columbia – (February 7th, 2023) – BioMark Diagnostics Inc. ...
With this partnership, the companies will offer an optimized workflow for a wide range of applications including liquid biopsy, sentinel pathogen testing, infectious disease assays, overall cancer research and drug discovery. ...
Such biomarker-based tests will also be essential for precisely monitoring a patient’s response to new ...
This unique public-private partnership between an innovative NHS organisaiton and a world leading cancer theranostic company is breaking down a significant barrier to biomarker testing helping clinical colleagues more easily personalise care for patients with cancer”. ...
“We are excited to transfer our knowledge and facilitate the routine use of comprehensive biomarker testing in other laboratories,” stated Jean-Pol Detiffe, Chief Strategy and Innovation Officer and Founder of OncoDNA. “While OncoDEEP has been our flagship biomarker test since 2014, we see more and more ...
The new precision molecular oncology research center will drive the development of targeted next-generation cancer therapies, including efforts to help people living with cancer benefit from molecular tests and targeted treatments through biomarker testing. Bayer has a 160-year track record of delivering scientific innovation for patients in ...
ByBayer AG
From a simple blood draw, the test identifies patients with actionable biomarkers more quickly than starting with tissue biopsy. The VHIO testing services will be available for clinical research and clinical care. “The opening of this service will give more patients with advanced cancer access to blood-based biomarker ...
” Highlights from the first quarter and recent weeks include: The American College of Gastroenterology (“ACG”) updated its clinical guideline for the diagnosis and management of esophageal precancer, endorsing, for the first time, nonendoscopic biomarker screening to detect precancer and prevent highly lethal esophageal cancer, providing support for ...
The updated guideline supports esophageal precancer screening utilizing Lucid’s EsoGuard® DNA Test on samples collected with its EsoCheck® Cell Collection Device, the only such nonendoscopic biomarker screening test available. ...
“Securing broad commercial reimbursement for EsoGuard testing is one of our most important near-term strategic goals and key value drivers. ...
“We are delighted to transfer our OncoDEEP technology to further enhance Synlab in the field of molecular diagnostics for clinical oncology,” stated Bernard Courtieu, CEO of OncoDNA. “Biomarker testing has the potential to improve patient outcomes and health quality. ...
OncoDNA has offered the OncoDEEP tissue-based biomarker test as a centralized laboratory developed test since 2014. Compared to single biomarker tests, the OncoDEEP test covers a comprehensive panel of genes and phenotypes known to be associated with cancer therapies – an approach used to ...
OncoDNA, amongst others, has been providing tissue-based biomarker testing and personalized liquid biopsy to support oncologists in their clinical recommendations. ...
OncoDNA, a genomic and theranostic company specializing in precision medicine, and Bergonié Institute, a non-profit private hospital entirely devoted to fighting cancer, today announced a new clinical trial to evaluate the use of comprehensive biomarker testing and liquid biopsy in 700 patients diagnosed with an advanced metastatic cancer. The Appolo study ...
In a separate development at CTAD, Suzanne Schindler, M.D., Ph.D., with Washington University School of Medicine, presented data from 1,085 individuals that showed the PrecivityAD™ blood test was highly concordant with CSF biomarkers and amyloid PET status in both cognitively normal (74% of those studied) and cognitively impaired (26%) individuals. The ...
In that role he led the commercialisation of the company’s suite of tests for biomarkers of organ rejection, including the flagship product TruGraf®, the only biomarker test for kidney transplant recipients approved for reimbursement by US national health insurance system administrator, the Centers for Medicare & ...
Lung cancer is the leading cause of cancer deaths worldwide.1 EGFR mutations are an important therapeutic target in NSCLC; EGFR Exon20 insertion mutations, specifically, are associated with resistance to immune checkpoint inhibitor therapies and poor patient prognosis.2 Further, EGFR Exon20 insertion mutations are often under-detected by conventional, single-gene testing ...
” The second abstract titled, “DNA methylation urine biomarkers test (EpiCheck® assay) in the diagnosis of upper tract urothelial carcinoma: results from a single-center prospective study,” evaluated the performance of Bladder EpiCheck in the detection of upper urinary tract urothelial carcinoma (UTUC) among 80 consecutive patients ...